Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous...
Product Name : Catiolanze
Product Type : HPAPI
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Product Name : Flarex
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 24, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tafluprost,Timolol Maleate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Product Name : Taptiqom
Product Type : HPAPI
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Tafluprost,Timolol Maleate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Product Name : Omlonti
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Visiox Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Harrow Acquires Santen’s Branded Ophthalmic Portfolio
Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...
Product Name : Flarex
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Fluorometholone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : UBE Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension...
Product Name : Omlonti
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : Omidenepag Isopropyl
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : UBE Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Glycerine,Poloxamer,Tyloxapol
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...
Product Name : Cationorm Plus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Glycerine,Poloxamer,Tyloxapol
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Santen EMA Filing for STN1013001 Cationic Emulsion in Glaucoma Treatment
Details : STN1013001 is a preservative-free latanoprost eye drop cationic emulsion, a prostaglandin F2α analogue, which is a selective proteinoid FP receptor agonist being developed for Open-Angle Glaucoma.
Product Name : Catiolanze
Product Type : HPAPI
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.
Product Name : Verkazia
Product Type : Peptide
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Santen Confirms Taflotan’S Efficacy in Reducing Intraocular Pressure, Inhibiting Glaucoma
Details : Taflotan (tafluprost) is the first preservative-free prostaglandin F2α analogue approved for the treatment open-angle glaucoma and in the management of ocular hypertension.
Product Name : Taptiqom
Product Type : HPAPI
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable